Parkinson's Canada (formerly Parkinson Foundation of Canada) is the national voice for Parkinson's disease in Canada, established in 1965. The organization serves as the primary non-profit dedicated to funding research, providing support services, and advocating for the approximately 110,000 Canadians living with Parkinson's disease[1]. The organization operates from headquarters in Toronto, Ontario, with a national network of regional chapters and support groups extending coast-to-coast.
Founded in 1965 as the Parkinson Foundation of Canada, the organization rebranded as Parkinson's Canada in 2015 to better reflect its comprehensive mission. The organization maintains a network of over 120 support groups across all provinces and territories, a toll-free helpline, and a robust research funding program that has awarded over $37 million since its inception[2].
Parkinson's Canada maintains collaborative relationships with leading research institutions including the Canadian Open Parkinson Network (C-OPN), University of Toronto, McGill University, and the University of British Columbia[1:1]. These partnerships enable the organization to fund cutting-edge research while ensuring research findings are translated into practical support for the Parkinson's community.
Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease, affecting approximately 1-2% of the population over 65 years of age and up to 4% of those over 85[3]. The disease is characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta, leading to the classic motor symptoms including resting tremor, bradykinesia, rigidity, and postural instability[4]. While the motor symptoms are defining features, non-motor symptoms including cognitive impairment, depression, sleep disorders, and autonomic dysfunction significantly impact quality of life and often precede motor diagnosis by years[5].
The pathogenesis of Parkinson's disease involves complex interactions between genetic susceptibility and environmental factors. Major genetic contributors include mutations in genes such as SNCA (alpha-synuclein), LRRK2, GBA, PARK2 (parkin), PINK1, and DJ-1, which collectively account for approximately 10-15% of cases, particularly those with early onset or family history[6]. Environmental factors including pesticide exposure, head trauma, and rural living have been implicated in epidemiological studies[7].
In Canada, Parkinson's disease affects approximately 110,000 individuals, with approximately 6,600 new diagnoses annually[8]. The prevalence is projected to increase substantially over the coming decades due to population aging. The average age at diagnosis is approximately 60 years, though approximately 10-20% of cases present before age 50, classified as early-onset Parkinson's disease[2:1].
The economic burden of Parkinson's disease in Canada is substantial, estimated at over $2.5 billion annually including direct medical costs, indirect costs from lost productivity, and informal caregiving expenses.
Parkinson's Canada's mission encompasses four primary pillars:
Parkinson's Canada's research strategy focuses on:
Parkinson's Canada offers several funding mechanisms for Canadian researchers:
Designed to kickstart careers for new investigators entering the Parkinson's research field. These grants provide seed funding for pilot projects that can generate preliminary data for larger grant applications.
Supports ongoing research programs for established scientists conducting significant Parkinson's research. These grants typically fund 2-3 year projects examining disease mechanisms, therapeutic targets, or clinical outcomes.
Postdoctoral fellowships supporting early-career researchers to train in Parkinson's-specific research environments. Since 1981, Parkinson's Canada has funded over 100 clinical and research fellowships.
Since 1981, Parkinson's Canada has provided:
This investment has supported research spanning basic neuroscience, translational medicine, and clinical trials, contributing to Canada's position as a leader in Parkinson's research.
Parkinson's Canada plays a key role in the Canadian Open Parkinson Network (C-OPN), a national cohort study that advances understanding of Parkinson's disease heterogeneity[1:2]. C-OPN brings together researchers from multiple Canadian institutions to study:
The network has recruited over 1,500 participants with Parkinson's disease and 500 controls across six participating sites, with plans for expansion. Standardized assessments include motor and non-motor symptom evaluations, imaging biomarkers, and biological sample collection.
Canadian researchers funded by Parkinson's Canada have contributed significantly to Parkinson's understanding:
Neuroimaging Advances: Canadian researchers have pioneered the use of transcranial ultrasound to detect nigral hyperechogenicity in Parkinson's disease, providing a potential biomarker for early diagnosis.
Genetic Studies: Canada's participation in international consortia has contributed to identification of novel Parkinson's risk genes including GCH1, DNAJC13, and SYT11.
Clinical Trials: Parkinson's Canada has facilitated Canadian participation in numerous international clinical trials for disease-modifying therapies, including trials of alpha-synuclein antibodies, LRRK2 inhibitors, and GBA-targeted interventions.
Parkinson's Canada provides comprehensive educational resources:
Parkinson's Canada maintains over 120 support groups across Canada, providing:
The CARE Fund provides financial assistance to people with Parkinson's facing financial hardship, helping cover:
An online tool helping individuals locate care services across Canada, including:
The Parkinson's Canada Helpline provides confidential support and information:
The helpline handled over 5,000 inquiries in 2023, with common topics including medication management, accessing healthcare services, financial assistance programs, and emotional support.
Parkinson's Canada connects researchers with human volunteers, recognizing that clinical trials are essential for developing new treatments. The organization:
The organization encourages patient participation in research through:
Parkinson's Canada advocates at the federal level for:
The organization works with provincial governments to:
Parkinson's Canada maintains relationships with international Parkinson's organizations, including:
Parkinson's Canada provides training resources for healthcare professionals:
The organization offers educational programming for patients and families:
Supporting the next generation of Parkinson's researchers through:
| Year | Milestone |
|---|---|
| 1965 | Founded as Parkinson Foundation of Canada |
| 1981 | Launched national research funding program |
| 1990s | Expanded national support group network |
| 2000 | Developed clinical practice guidelines |
| 2015 | Rebranded as Parkinson's Canada |
| 2020 | Launched national research strategy |
| 2021 | Reaccredited by Imagine Canada |
| 2023 | Expanded support services and digital resources |
Parkinson's Canada-funded research has contributed to advances in:
Understanding the mechanisms of dopaminergic neuron degeneration, alpha-synuclein aggregation, and Lewy body formation[9][10].
Supporting research into Parkinson's-associated genes including LRRK2, GBA, SNCA, and PARK genes[11][12].
Funding clinical trials of disease-modifying therapies, including:
Research addressing cognitive impairment, depression, sleep disorders, and autonomic dysfunction that significantly impact quality of life[13].
Parkinson's Canada collaborates with:
Parkinson's Canada operates through provincial and territorial branches:
The largest provincial presence with the most support groups, research partnerships, and healthcare professional training programs.
French-language resources and support, including partnerships with Quebec neuroscience centers.
Alberta, British Columbia, Saskatchewan, and Manitoba programs emphasizing rural and remote community support.
Nova Scotia, New Brunswick, Prince Edward Island, Newfoundland and Labrador programs focused on access to specialized care.
Territorial programs addressing the unique challenges of providing support in remote communities.
Parkinson's Canada works with corporate partners through:
Research partnerships with Canadian universities:
Collaboration with:
Parkinson's Canada has outlined several strategic priorities for the coming years:
Marras C, et al. Advancing Parkinson's Disease Research in Canada: The Canadian Open Parkinson Network (C-OPN) Cohort. J Parkinsons Dis. 2024. ↩︎ ↩︎ ↩︎
Grimes D, et al. Canadian guideline for Parkinson disease. J Parkinsons Dis. 2019. ↩︎ ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015. ↩︎
Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008. ↩︎
Postuma RB, et al. MDS consensus criteria for prodromal Parkinson's disease. Mov Disord. 2015. ↩︎
Schapira AH, et al. Parkinson's disease: from origins to treatment. Brain. 2019. ↩︎
Wirdefeldt K, et al. Epidemiology and etiology of Parkinson's disease. Handb Clin Neurol. 2015. ↩︎
Pringsheim T, et al. The prevalence of Parkinson's disease. Mov Disord. 2014. ↩︎
Jellinger KA. Pathology of Parkinson's disease. Mov Disord. 1999. ↩︎
Braak H, et al. Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson disease. Neurobiol Aging. 2003. ↩︎
Foltynie T, et al. Parkinson's disease genetics: establishing pathogenic mutations and variants. Brain. 2024. ↩︎
Singleton A, et al. Genetics of Parkinson disease. Nat Rev Neurol. 2013. ↩︎
Aarsland D, et al. Parkinson disease-associated cognitive impairment. Nat Rev Neurol. 2021. ↩︎